Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced a conference call and webcast set for May 9, 2023, at 4:30 p.m. ET to discuss its first quarter financial results. The press release detailing these results will be available after the market closes on the same day. Investors can access the live webcast and subsequent archive through the company’s investor website. Arcutis focuses on developing innovative treatments for immune-mediated dermatological diseases, boasting a robust pipeline targeting conditions like psoriasis and atopic dermatitis. Investors are advised to stay tuned for the upcoming earnings call and associated materials.